Good morning, 360!

If you’ve been in the Market Master’s Room lately, then you know Jeff Williams! Just a quick note that $300 off his flagship options service still in effect. Be the best prepared trader on the Street!

FOCUS LIST🔎

TPST – Up over 50% in the pre-market after announcing positive new data in its Phase 1b/2  study for treatment of hepatocellular carcinoma (HCC)

TRVN – Up over 80% in pre after announcing TRV045 demonstrated statistically significant anti-seizure activity in Epilepsy models

AUGX – Up over 4% in pre after announcing it has partnered with Emergency Services inc. to introduce generative AI solution that relieves clinician burnout in emergency departments

*sponsored by Shore Thing Media

Do you remember the stock – NITO (N2OFF) – I showed you on Monday?

It was one of the wildest trading days we have seen in a long time.

NITO gained nearly 100% in the opening hour of trading on Monday… before it took a pretty insane nose dive.

I thought it had explosive “bottom bouncer” potential, but I had no idea it could move that fast (in either direction!).

Today may be a chance to “reload” on a dip… but the question is always, “Where to rebuy?”

I like to use a 5-minute chart for my intraday trading.

Stocks breaking out above the 20-moving average (the yellow line on the chart below) on a 5-minute timeframe are my favorite to buy.

Below is the NITO chart since Monday’s explosion…

The stock rebounded well on Tuesday as it gained over 10% that day.

I am looking to see if those gains hold, and if it can build more on top of that from these levels.

I doubt we’ll see another 90%+ move like Monday, but NITO has certainly shown us that it can wake up and make big moves when it wants to.

So keep NITO on the top of your trading radar today!

As always, If you decide to trade anything, do your own due diligence and have a trading plan in place as trading is risky and nothing is ever guaranteed.

*Sponsored content/paid advertisement. This investment involves substantial risk. Please see full disclosure below, and detailed discussion of risks and atypical results.

HOTLIST🔥

TPST – Up over 50% in the pre-market after announcing positive new data in its Phase 1b/2  study for treatment of hepatocellular carcinoma (HCC)

Tempest Therapeutics Inc. (TPST) is a clinical-stage oncology company that develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors.

In the pre-market this morning, the company announced that Amezalpat (TPST-1120) Arm, improves all efficacy endpoints vs. SoC control in its  first line Hepatocellular Carcinoma (HCC) trial.

The study showed:

Six-month improvement in median OS over control arm (21 months vs. 15 months)

20/40 patients remain in survival follow up in amezalpat/TPST-1120 arm vs. 9/30 in control

The stock traded up over 50% in the pre-market in reaction to the results.

The $4.10 area acted as support in the pre-market and will be an important level to watch.

Above it, targets to the upside are $4.50, $5 and then the pre-market high at $5.78. Beyond that, $6, $7.50 and $9 come into play.

Below $4.10, targets to the downside are $3.50, $3 and then a gap fill at $2.85.

TRVN – Up over 80% in pre after announcing TRV045 demonstrated statistically significant anti-seizure activity in Epilepsy models

Trevena Inc. (TRVN) is a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders.

In the pre-market this morning, the company announced preclinical TRV045 data providing insight into novel mechanism of Analgesic Effect in Chronic Neuropathic Pain Model and demonstrating statistically significant anti-seizure activity in Epilepsy models.

TRV045 shows potential for sustained, long-term analgesic effect in preclinical model of neuropathic pain, with no evidence of receptor desensitization

TRV045 demonstrates statistically significant, dose-dependent increase in measures of seizure threshold and shows seizure protection in validated preclinical models

The stock traded up over 80% in the pre-market in reaction to the results.

$0.45 acted as support in the pre-market and will be an important level to watch. 

Above it, targets to the upside are $0.55 and then the pre-market high at $0.81. Beyond that, $0.90 and $1 come into play.

Below $0.45, targets to the downside are $0.40 and then a gap fill at $0.3544 with $0.30 below that.

AUGX – Up over 4% in pre after announcing it has partnered with Emergency Services inc. to introduce generative AI solution that relieves clinician burnout in emergency departments

Augmedix, Inc. (AUGX) provides ambient AI medical documentation and data solutions.

In the pre-market this morning, the company announced that Emergency Services Inc., a physician-owned emergency medicine services group in Columbus, Ohio, is introducing Augmedix Go ED to physicians in the emergency department (ED) at the second-largest healthcare system in central Ohio.

Augmedix Go ED is the industry’s first fully automated, generative AI (GenAI) powered medical documentation product for EDs nationwide.

“Given the unique needs of the ED, it has been difficult to identify a documentation solution that effectively alleviates the administrative burden on our physicians – until we were introduced to Augmedix Go ED,” said Eric Drobny, MD, CFO at Emergency Services Inc.

AUGX traded up over 4% in the pre-market in reaction to the partnership announcement this morning.

The first target for bulls is the pre-market high at  $0.7853.

Beyond that, targets to the upside are $0.80, $0.8677, $1 and then $1.23. Above that, there is a gap fill at $2.34.

Below $0.7853, there is a gap fill at $0.75, below which is all-time lows in the stock.

MARKET NEWS 📰

👊 Make sure you are getting my mobile text alerts –  text “RAGE” to 1-(888) 404-5747 to get all of my latest HOT STOCK ideas delivered right to your phone (make sure you put the “1” at the front!).  Don’t miss out!

Questions or concerns about our products? Email Support@360wallstreet.io © Copyright 2022, RagingBull

*Just so you know, what you’re reading is curated content for which we have received a monetary fee (detailed below) to create and distribute. Let’s be clear that investing can be quite the roller coaster as stock prices can have wild swings up and down, so consider those crucial risks before you ever consider trading anything we discuss. Make sure you check out our full disclosure down below for the details on how we were paid, the risks, and why these results aren’t what you’d call “typical.”

Just a quick heads up about this ad you’re reading—as we’ve said, even though we like the company referenced above, and all the facts we discussed above are true to the best of our knowledge, we are running a business here. To distribute this information and help offset the costs of maintaining our large digital audience, in advance of writing the content above, we received sixty thousand dollars (cash) from Shore Thing Media for advertising N2OFF, Inc for a five day marketing program starting on June 17, 2024. This amount was paid by someone else not connected to N2OFF, Inc. It might be obvious, but whoever paid for this might own shares and is likely looking to sell some or all of them at any time after we send out this information, which might affect the stock price. We may also buy or sell shares in the company at some point in the future, although neither RagingBull nor its owners own any shares of the company at this time. Also, keep in mind that due to the sheer size of our audience, if even a small percentage of people decide they want to buy this stock, it could potentially boost interest enough to hike up those share prices and cause a temporary spike, and the opposite is possible as our program ends, though that is not always the case.

Now, diving right into N2OFF, Inc might sound exciting. But remember, it’s like venturing into the wilderness—be aware that there’s exceptional risk involved in trading. This isn’t small potatoes we’re talking about; you could lose every dime you put in, so always carefully think about what you’re doing. That’s why they call this trading, after all. We’re shining a light on the good stuff about the company here, but it’s on you to do your homework, make your own calls, and determine a plan for your own trading, hopefully with the help of your professional 1nvestment advis0r.

Oh, that brings us to another crucial point—we’re not here to tell you (or even recommend) what you should do with your hard-earned money. We’re simply sharing our non-expert thoughts by highlighting some companies we like that could use some help telling their story to more people. We’re obviously biased in our writing. We’re not here to dig into anything that may be negative about the company; this is advertising, after all! Also, keep in mind that if we make some predictions about the future, these are technically known as “forward-L00king statements” under the securities acts, so take those with a grain of salt. As with all forecasts, they’re not set in stone, often wrong, and we certainly can’t know where the Company’s earnings, business, or share price will be tomorrow or a year from now.

Everything you read from us is all for your education, information, and possible entertainment. While we believe the info is reliable and accurate, we can’t wear a cape and guarantee it. Before you jump into anything, make sure to talk it over with a pro—someone you trust who’s licensed to give you real advice. To be clear, 

Neither Raging Bull nor its owners, employees, or independent contractors are registered as a secur1ties br0ker-dealer, br0ker, 1nvestment advis0r (IA), or IA rep’s with the SEC, any state securities regulat0ry authority, or any self-regulat0ry organization.

So, that’s the scoop! If you’re intrigued and want to learn more about the companies we talk about, hit up the SEC’s website to dig into their filings and see the full picture.